WallStSmart

GE Vernova LLC (GEV)vsEli Lilly and Company (LLY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Eli Lilly and Company generates 83% more annual revenue ($72.25B vs $39.38B). LLY leads profitability with a 35.0% profit margin vs 23.8%. LLY appears more attractively valued with a PEG of 1.40. LLY earns a higher WallStSmart Score of 78/100 (B+).

GEV

Strong Buy

67

out of 100

Grade: B-

Growth: 8.0Profit: 7.0Value: 4.3Quality: 4.3
Piotroski: 4/9Altman Z: 1.02

LLY

Strong Buy

78

out of 100

Grade: B+

Growth: 10.0Profit: 10.0Value: 5.0Quality: 6.5
Piotroski: 6/9Altman Z: 2.06

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GEV6 strengths · Avg: 9.2/10
Market CapQuality
$300.69B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
75.7%10/10

Every $100 of equity generates 76 in profit

EPS GrowthGrowth
1816.0%10/10

Earnings expanding 1816.0% YoY

Profit MarginProfitability
23.8%9/10

Keeps 24 of every $100 in revenue as profit

Revenue GrowthGrowth
16.3%8/10

16.3% revenue growth

Free Cash FlowQuality
$4.79B8/10

Generating 4.8B in free cash flow

LLY6 strengths · Avg: 10.0/10
Market CapQuality
$869.41B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
107.5%10/10

Every $100 of equity generates 108 in profit

Profit MarginProfitability
35.0%10/10

Keeps 35 of every $100 in revenue as profit

Operating MarginProfitability
49.4%10/10

Strong operational efficiency at 49.4%

Revenue GrowthGrowth
55.5%10/10

Revenue surging 55.5% year-over-year

EPS GrowthGrowth
169.9%10/10

Earnings expanding 169.9% YoY

Areas to Watch

GEV4 concerns · Avg: 3.0/10
PEG RatioValuation
1.864/10

Expensive relative to growth rate

P/E RatioValuation
32.7x4/10

Premium valuation, high expectations priced in

Price/BookValuation
20.1x2/10

Trading at 20.1x book value

Altman Z-ScoreHealth
1.022/10

Distress zone — elevated risk

LLY3 concerns · Avg: 3.0/10
P/E RatioValuation
34.7x4/10

Premium valuation, high expectations priced in

Debt/EquityHealth
1.603/10

Elevated debt levels

Price/BookValuation
27.2x2/10

Trading at 27.2x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : GEV

The strongest argument for GEV centers on Market Cap, Return on Equity, EPS Growth. Profitability is solid with margins at 23.8% and operating margin at 5.5%. Revenue growth of 16.3% demonstrates continued momentum.

Bull Case : LLY

The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.

Bear Case : GEV

The primary concerns for GEV are PEG Ratio, P/E Ratio, Price/Book.

Bear Case : LLY

The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.

Key Dynamics to Monitor

GEV carries more volatility with a beta of 1.31 — expect wider price swings.

LLY is growing revenue faster at 55.5% — sustainability is the question.

GEV generates stronger free cash flow (4.8B), providing more financial flexibility.

Monitor SPECIALTY INDUSTRIAL MACHINERY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

LLY scores higher overall (78/100 vs 67/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

GE Vernova LLC

INDUSTRIALS · SPECIALTY INDUSTRIAL MACHINERY · USA

GE Vernova LLC, an energy business company, generates electricity.

Visit Website →

Eli Lilly and Company

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.

Visit Website →

Want to dig deeper into these stocks?